Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Cyramza (Ramucirumab) Market Growth Potential: How Will Market Size Shift Through 2030?
The cyramza (ramucirumab) market has shown significant expansion in recent years, with its valuation expected to climb from $1.31 million in 2025 to $1.4 million in 2026, reflecting a compound annual growth rate (CAGR) of 6.7%. This historical growth is largely due to its approval for gastric and colorectal cancers, the increasing worldwide incidence of cancer, the clinical efficacy of VEGFR inhibitors, its adoption within hospital oncology departments, and a scarcity of late-stage treatment options.
The market for cyramza (ramucirumab) is projected to experience robust expansion over the coming years. Its valuation is set to reach $1.79 million by 2030, demonstrating a compound annual growth rate (CAGR) of 6.3%. This anticipated growth throughout the forecast period stems from factors such as a rising incidence of solid tumors, the broadening of its application into novel oncology indications, the advancement of targeted cancer treatments, an increase in oncology healthcare expenditures, and enhanced diagnostic accuracy. Key trends during this period are expected to encompass the increasing adoption of anti-angiogenic therapies, its usage spreading across various cancer types, its combination with chemotherapy regimens, a heightened demand for treating advanced-stage cancers, and its administration predominantly within hospital oncology settings.
Get A Free Sample Report With In-Depth Market Insights:
Cyramza (Ramucirumab) Market Growth Factors: What’s Supporting Expansion?
The growth of the Cyramza (ramucirumab) market is anticipated to be significantly boosted by the escalating incidence of cancer. Cancer encompasses a range of illnesses characterized by uncontrolled cellular proliferation and subsequent metastasis throughout the body. The increase in cancer cases stems from various factors, including an aging population, lifestyle choices, environmental exposures, enhanced detection methods, and genetic predispositions. Cyramza (ramucirumab) functions in cancer therapy by targeting and inhibiting the vascular endothelial growth factor receptor 2 (VEGFR-2), thereby hindering tumor blood vessel formation and slowing disease progression. For example, a report from the Australian Institute of Health and Welfare, an Australia-based national agency, indicated in August 2024 that Australia is projected to record approximately 209,000 new cancer diagnoses by 2034, a notable rise from the estimated 169,000 cases in 2024, reflecting population growth and increasing cancer rates. Furthermore, in 2024, cancer is expected to be responsible for about 3 out of every 10 deaths nationwide. Consequently, the rising prevalence of cancer is a key factor propelling the Cyramza (ramucirumab) market forward. The expanding older demographic is projected to stimulate the growth of the Cyramza (Ramucirumab) market. An aging population refers to a higher proportion of elderly individuals within a society, a trend resulting from increased life expectancy and decreased birth rates. This demographic shift is largely due to medical advancements that have prolonged human life. Cyramza (Ramucirumab) is utilized by the elderly to manage advanced cancers by impeding the blood vessel development that fuels tumor growth. As an illustration, in January 2024, the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is predicted to climb from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Over this period, this age group’s share of the total U.S. population is expected to rise from 17% to 23%. Thus, the growth in the aging population is driving the expansion of the Cyramza (Ramucirumab) market.
Cyramza (Ramucirumab) Market Breakdown By Product Type And Application
The cyramza (ramucirumab) market covered in this report is segmented –
1) By Type: 100mg/Box, 500mg/Box
2) By Application: Advanced Gastric Cancer, GEJ Adenocarcinoma, Non-small Cell Lung Carcinoma, Metastatic Colorectal Cancer (mCRC), Hepatocellular Carcinoma (HCC)
3) By End-User: Hospitals, Cancer Treatment Centers, Ambulatory Surgical Centers, Research Institutes
Cyramza (Ramucirumab) Market Company Landscape And Competitive Strategy
Major companies operating in the cyramza (ramucirumab) market are Eli Lilly and Company
View The Full Cyramza (Ramucirumab) Market Report:
Cyramza (Ramucirumab) Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the cyramza (ramucirumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cyramza (ramucirumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
